KORU Medical Systems (NASDAQ:KRMD) Q4 2019 Earnings Conference Call February 26, 2020 9:00 AM ET Company Participants Devin Sullivan - SVP, Equity Group Don Pettigrew - President and CEO Karen Fisher - CFO Conference Call Participants Alex Nowak - Craig-Hallum Capital Group Andrew DeSilva - B. Riley FBR Operator Greetings and welcome to the KORU Medical Systems Fourth Quarter and Full Year 2019 Financial Results Conference Call. At this time, all participants are in a listen-only mode. A brief question-and- ...

NOT CALS TEMS | TM Q4 and FY 2019 CONFERENCE CALL February 26, 2020 Nasdaq: KRMD DISCLAIMER / NON-GAAP MEASURES This presentation contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "plan," "goal," "seek," "vision, "confident," "future," "will" and similar references to future periods. Examples of forward-looking statements include, among others, sta ...

KORU Medical Systems (NASDAQ:KRMD) Q3 2019 Earnings Conference Call November 6, 2019 9:00 AM ET CompanyParticipants Devin Sullivan - SVP, Equity Group Don Pettigrew - President & CEO Karen Fisher - CFO Conference Call Participants Alex Nowak - Craig-Hallum Operator Greetings and welcome to the KORU Medical Systems Reports Third Quarter 2019 Financial Results Conference Call. [Operator Instructions] It is now my pleasure to introduce your host, Devin Sullivan, Senior Vice President of The Equity Group. Thank ...

Q3 2019 CONFERENCE CALL November 6, 2019 Nasdaq: KRMD DISCLAIMER / NON-GAAP MEASURES This presentation contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "plan," "goal," "seek," "vision, "confident," "future," "will" and similar references to future periods. Examples of forward-looking statements include, among others, statements we make regarding o ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2019 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________. Commission File Number: 0-12305 REPRO MED SYSTEMS, INC. (Exact name of registrant as specified in its charter) New York 13-30448 ...

HIgHoFlo Super26" Subcutaneous Safety Needle Sets INVESTOR PRESENTATION Dougherty & Co. Institutional Investor Conference September 2019 OTCQX: REPR INVESTOR PRESENTATION JUNE 26, 2019 Home and Specialty Infusion Products that Improve the Patient Experience DISCLAIMER & NON-GAAP MEASURES OTCQX: REPR This presentation contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified ...

Repro Med Systems, Inc. (REPR) Q2 2019 Earnings Conference Call August 8, 2019 9:00 AM ET Company Participants Devin Sullivan - SVP, Equity Group Don Pettigrew - President & CEO Karen Fisher - CFO Manuel Marques - COO Conference Call Participants Alex Nowak - Craig-Hallum Operator Greetings and welcome to the RMS Medical Second Quarter 2019 Financial Results conference call. [Operator Instructions]. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host Devin Sulliva ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2019 Or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________. Commission File Number: 0-12305 REPRO MED SYSTEMS, INC. (Exact name of registrant as specified in its charter) N/A (Former Name, Form ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2019 Or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Identification No.) 24 Carpenter Road, Chester, New York 10918 (Address of Principal Executive Offices) ( ...

PART I This section covers the company's business, products, and strategy, key risk factors, properties, and ongoing legal proceedings [Business](index=4&type=section&id=Item%201.%20Business) Repro Med Systems, Inc. (RMS) designs, manufactures, and markets proprietary portable medical devices for the ambulatory infusion market, with its primary product being the FREEDOM Infusion System. The company's strategy focuses on becoming a preferred drug delivery partner, targeting significant revenue and margin growth by 2022. Sales are highly concentrated, with five distributors accounting for 75% of gross revenues, and one US distributor alone representing 58%. Manufacturing is conducted at a single facility in Chester, NY, with reliance on some single-source suppliers for components [Our Business, Mission, and Strategy](index=4&type=section&id=Our%20Business%2C%20Mission%2C%20and%20Strategy) The company designs, manufactures, and markets proprietary portable medical devices, focusing on improving patient quality of life through innovative solutions - The company designs, manufactures, and markets proprietary portable medical devices, primarily the FREEDOM Infusion System, for the ambulatory infusion market[13](index=13&type=chunk) - The company's mission is to improve patient quality of life through high-quality, innovative, and easy-to-use therapeutic solutions for home or alternate site settings[14](index=14&type=chunk)[15](index=15&type=chunk) Strategic Financial Goals Through 2022 | Goal | Target | | :--- | :--- | | Net Revenue Run Rate | $50 million | | Gross Margins | 70%+ | | Annual Organic Revenue Growth | 20%+ | [Our Products](index=5&type=section&id=Our%20Products) The core product is the FREEDOM System, including syringe drivers and needle sets, cleared for specific immune globulin therapies - The core product is the FREEDOM System, which includes the FREEDOM60® and FreedomEdge® Syringe Drivers, HIgH-Flo Subcutaneous Safety Needle Sets™, and RMS Precision Flow Rate Tubing™[18](index=18&type=chunk) - The FREEDOM System received FDA 510(k) clearance in August 2017 and is specifically cleared for leading immune globulins like Hizentra® and Cuvitru®[19](index=19&type=chunk) [Sales, Manufacturing, and R&D](index=6&type=section&id=Sales%2C%20Manufacturing%2C%20and%20R%26D) Sales are highly concentrated among a few distributors, with all manufacturing at a single facility relying on third-party suppliers - Sales are highly concentrated, with five distributors comprising approximately **75% of gross revenues**. A single US distributor accounts for about **58% of gross revenues**[23](index=23&type=chunk) - International sales, primarily in Europe and the UK, accounted for approximately **11% of gross revenues in 2018**[23](index=23&type=chunk) - All product assembly and packaging occurs at the Chester, NY facility. The company relies on third-party suppliers for all components, with some being single-sourced[25](index=25&type=chunk)[26](index=26&type=chunk) Research and Development Spending | Year | Amount (millions) | | :--- | :--- | | 2018 | $0.2 | | 2017 | $0.1 | [Regulatory, Competition, and Intellectual Property](index=6&type=section&id=Regulatory%2C%20Competition%2C%20and%20Intellectual%20Property) The company's devices are subject to complex FDA regulations, face diverse competition, and are protected by patents and pending applications - The company's devices are subject to complex regulations by the FDA and other governmental authorities. The FDA has announced intentions to reform the 510(k) clearance pathway, which could impact the business[28](index=28&type=chunk)[30](index=30&type=chunk) - Competition includes electronic pumps, elastomeric pumps, and other mechanical pumps, with differentiators being safety, ease of use, and cost-effectiveness[32](index=32&type=chunk) - The company holds four issued patents with expiration dates from 2021 to 2031 and has twelve pending applications[34](index=34&type=chunk) [Employees and Executive Officers](index=7&type=section&id=Employees%20and%20Executive%20Officers) This section details the company's employee count and lists its key executive officers - As of December 31, 2018, the company had **75 full-time employees** and **1 part-time employee**[33](index=33&type=chunk) Executive Officers (as of March 5, 2019) | Name | Age | Position | | :--- | :--- | :--- | | Donald B. Pettigrew | 51 | President and Chief Executive Officer | | Karen Fisher | 52 | Chief Financial Officer and Treasurer | | Manuel Marques | 46 | Chief Operating Officer | | Daniel S. Goldberger | 60 | Executive Chairman | [Risk Factors](index=8&type=page&id=Item%201A.%20Risk%20Factors) The company faces substantial risks, including intense competition from larger firms, potential obsolescence from technological advancements, and complex, evolving FDA regulations, particularly potential changes to the 510(k) clearance process. Business operations are vulnerable due to reliance on a single manufacturing facility, a few key distributors, and single-source suppliers. Significant legal risks exist from ongoing patent litigation with competitor EMED. Ownership risks include high stock concentration with two entities controlling a combined ~49% of shares and limited trading liquidity on the OTCQX market - **Business Risks:** The company faces risks from intense competition, technological disruption, complex regulations (especially FDA 510(k) changes), reliance on a few distributors and single-source suppliers, and ongoing patent litigation with EMED[42](index=42&type=chunk)[47](index=47&type=chunk)[63](index=63&type=chunk) - **Operational Risks:** The company's products are manufactured at a single facility, making operations vulnerable to interruption. It also relies on single suppliers for critical components, including molded plastic parts from Taiwan and tubing from a US supplier[59](index=59&type=chunk)[74](index=74&type=chunk) - **Litigation Risk:** The company is involved in several lawsuits with its competitor, EMED Technologies Corporation, regarding patent infringement. An adverse outcome could materially and adversely affect the business[63](index=63&type=chunk) - **Ownership Risks:** There is a significant concentration of share ownership, with Horton Freedom, L.P. and FirstLight Asset Management, LLC beneficially owning approximately **31%** and **18%**, respectively. The stock also has a limited public trading market on the OTCQX[94](index=94&type=chunk)[98](index=98&type=chunk) [Unresolved Staff Comments](index=18&type=section&id=Item%201B.%20Unresolved%20Staff%20Comments) This item is not applicable to the company - Not applicable[105](index=105&type=chunk) [Properties](index=18&type=section&id=Item%202.%20Properties) The company leases its headquarters, manufacturing, and R&D facility in Chester, New York. The lease has been extended with options through August 2022. The landlord is a director of the company. RMS also leases a small storage space and owns an adjacent residential property that it intends to sell - The company leases its main facility at 24 Carpenter Road, Chester, New York, which serves as its headquarters, manufacturing site, and R&D center[106](index=106&type=chunk) - A lease extension provides for six-month renewal options through August 2022. The landlord is a director of RMS[107](index=107&type=chunk) [Legal Proceedings](index=19&type=section&id=Item%203.%20Legal%20Proceedings) The company is engaged in multiple, ongoing lawsuits with its principal competitor, EMED Technologies Corporation. The litigation, initiated in 2013, involves allegations of patent infringement by RMS's needle sets, as well as claims of antitrust violations and unfair business practices. The cases are proceeding in various U.S. District Courts, and while RMS believes it has meritorious defenses, an adverse outcome could materially impact the company - The company is involved in several lawsuits with its principal competitor, EMED Technologies Corporation, concerning allegations that RMS's needle sets infringe on various EMED patents[110](index=110&type=chunk) - The legal disputes include multiple cases across different jurisdictions, such as the Eastern District of California and the Southern District of New York, involving patents '703, '476, and '576[111](index=111&type=chunk)[114](index=114&type=chunk)[116](index=116&type=chunk) - While the company is vigorously defending its position and believes it has meritorious defenses, the outcomes are uncertain and could have a material adverse effect on the business if unsuccessful[110](index=110&type=chunk)[122](index=122&type=chunk) [Mine Safety Disclosures](index=20&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This item is not applicable to the company - Not applicable[123](index=123&type=chunk) PART II This section presents the company's market information, financial performance analysis, audited financial statements, and disclosures on internal controls and other corporate matters [Market for the Registrant's Common Equity and Related Stockholder Matters and Issuer Purchases of Equity](index=20&type=section&id=Item%205.%20Market%20for%20the%20Registrant%27s%20Common%20Equity%20and%20Related%20Stockholder%20Matters%20and%20Issuer%20Purchases%20of%20Equity) The company's common stock trades on the OTCQX market under the symbol "REPR". No cash dividends have been paid, and none are planned for the foreseeable future. A stock repurchase program authorized in 2015 has been inactive since June 2017 to preserve cash for business expansion - The company's common stock is traded on the OTCQX market under the symbol "REPR"[126](index=126&type=chunk) - No cash dividends have ever been paid, and the company intends to use available funds for business operations rather than pay dividends in the foreseeable future[126](index=126&type=chunk) - A stock repurchase program authorized in 2015 was discontinued in June 2017 to utilize cash for capital investments. As of December 31, 2018, **1,603,394 shares** remained available for repurchase under the plan[128](index=128&type=chunk) [Selected Financial Data](index=21&type=section&id=Item%206.%20Selected%20Financial%20Data) This item is not applicable to the company - Not applicable[130](index=130&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=21&type=section&id=Item%207.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) In 2018, RMS underwent significant management changes, including the termination of its CEO. The company achieved record net sales of $17.4 million, a 12.4% increase from 2017, driven by higher needle set sales. Gross margin improved to 62.3% from 60.0% due to operating efficiencies. Net income was $0.9 million, slightly up from $0.8 million in 2017, despite incurring $1.0 million in one-time reorganization charges. The company maintains a solid liquidity position with $5.3 million in cash and equivalents and believes it is sufficiently funded for the next 12 months [Overview](index=21&type=section&id=Overview) The company experienced significant leadership changes in 2018, achieving record net sales despite one-time reorganization charges - The company experienced significant leadership changes in 2018, including the termination of CEO Andrew I. Sealfon and the appointment of a new management team[134](index=134&type=chunk)[135](index=135&type=chunk) - A Special Committee was formed to investigate issues related to the former CEO, which concluded with a stock sale agreement and mutual releases in December 2018[137](index=137&type=chunk)[140](index=140&type=chunk) - The company achieved record net sales of **$17.4 million** for the twelve months ended December 31, 2018[143](index=143&type=chunk) - Organizational changes resulted in aggregate operating expenses increasing by **$1.0 million** for the twelve months ended December 31, 2018[145](index=145&type=chunk) - Despite reorganization charges, the company ended 2018 with **$0.9 million in net income** and **$5.3 million of cash on hand** (including a $1.5 million CD)[146](index=146&type=chunk) [Results of Operations](index=23&type=section&id=Results%20of%20Operations) This section details the company's net sales, gross profit, and net income performance, highlighting key expense drivers Net Sales Comparison (Twelve Months Ended Dec 31) | Region | 2018 | 2017 | Change ($) | Change (%) | | :--- | :--- | :--- | :--- | :--- | | Domestic | $14,235,689 | $12,615,121 | $1,620,568 | 12.9% | | International | $3,118,048 | $2,827,591 | $290,457 | 10.3% | | **Total** | **$17,353,737** | **$15,442,712** | **$1,911,025** | **12.4%** | Gross Profit Comparison (Twelve Months Ended Dec 31) | Metric | 2018 | 2017 | Change ($) | Change (%) | | :--- | :--- | :--- | :--- | :--- | | Gross Profit | $10,810,488 | $9,268,107 | $1,542,381 | 16.6% | | Gross Margin | 62.3% | 60.0% | - | - | - Selling, general and administrative (SG&A) expenses increased by **$1.4 million (17.6%) in 2018**, primarily due to **$0.8 million in legal fees** and **$0.6 million in reorganization costs** related to management changes[156](index=156&type=chunk) Net Income Comparison (Twelve Months Ended Dec 31) | Metric | 2018 | 2017 | | :--- | :--- | :--- | | Net Income | $910,570 | $819,547 | | % of Net Sales | 5.2% | 5.3% | [Liquidity and Capital Resources](index=26&type=section&id=Liquidity%20and%20Capital%20Resources) The company's liquidity, primarily from cash and credit, is deemed sufficient for future operations and capital expenditures - As of December 31, 2018, the company's principal sources of liquidity were **$3.7 million in cash**, a **$1.5 million certificate of deposit**, and an undrawn **$1.5 million line of credit**[162](index=162&type=chunk) - Management believes cash on hand and cash from operations will be sufficient to fund operations, R&D, and capital expenditures for the next 12 months[163](index=163&type=chunk) Summary of Cash Flows | Activity | Twelve Months Ended Dec 31, 2018 | Ten Months Ended Dec 31, 2017 | | :--- | :--- | :--- | | Net cash provided by operating activities | $1,479,662 | $899,912 | | Net cash used in investing activities | $(1,729,824) | $(219,281) | | Net cash provided by/(used in) financing activities | $14,429 | $(19,360) | [Non-GAAP Financial Measures](index=27&type=section&id=Non-GAAP%20Financial%20Measures) This section reconciles GAAP net income to Non-GAAP Adjusted EBITDA, providing an alternative view of financial performance Reconciliation of GAAP Net Income to Non-GAAP Adjusted EBITDA | Line Item | Twelve Months Ending Dec 31, 2018 | Twelve Months Ending Dec 31, 2017 | | :--- | :--- | :--- | | GAAP Net Income | $910,570 | $819,547 | | Tax Expense | $266,380 | $390,799 | | Depreciation/Amortization | $309,263 | $306,562 | | Interest Income | $(28,104) | $(3,743) | | Reorganization Charges | $996,447 | — | | Stock Compensation Expense | $293,040 | $66,947 | | **Non-GAAP Adjusted EBITDA** | **$2,747,596** | **$1,580,112** | [Quantitative and Qualitative Disclosures about Market Risk](index=29&type=section&id=Item%207A.%20Quantitative%20and%20Qualitative%20Disclosures%20about%20Market%20Risk) This item is not applicable to the company - Not applicable[185](index=185&type=chunk) [Financial Statements and Supplementary Data](index=29&type=section&id=Item%208.%20Financial%20Statements%20and%20Supplementary%20Data) This section presents the company's audited financial statements for the twelve months ended December 31, 2018, and the ten months ended December 31, 2017. Key statements include the Balance Sheets, Statements of Operations, and Statements of Cash Flows, accompanied by an independent auditor's report and detailed notes. As of year-end 2018, total assets were $10.5 million and total stockholders' equity was $9.0 million. For fiscal year 2018, the company reported net sales of $17.4 million and net income of $0.9 million [Financial Statements](index=31&type=section&id=Financial%20Statements) This section presents the company's audited balance sheets, statements of operations, and statements of cash flows Balance Sheet Summary (as of Dec 31) | Account | 2018 | 2017 | | :--- | :--- | :--- | | Total Current Assets | $9,033,054 | $7,929,174 | | **Total Assets** | **$10,545,039** | **$9,280,860** | | Total Current Liabilities | $1,584,232 | $1,585,696 | | **Total Liabilities** | **$1,584,232** | **$1,611,133** | | **Total Stockholders' Equity** | **$8,960,807** | **$7,669,727** | Statement of Operations Summary (Twelve Months Ended Dec 31, 2018) | Account | Amount | | :--- | :--- | | Net Sales | $17,353,737 | | Gross Profit | $10,810,488 | | Net Operating Profit | $1,164,536 | | **Net Income** | **$910,570** | Statement of Cash Flows Summary (Twelve Months Ended Dec 31, 2018) | Activity | Amount | | :--- | :--- | | Net Cash from Operating Activities | $1,479,662 | | Net Cash used in Investing Activities | $(1,729,824) | | Net Cash from Financing Activities | $14,429 | | **Net Decrease in Cash** | **$(235,733)** | [Notes to Financial Statements](index=35&type=section&id=Notes%20to%20Financial%20Statements) This section provides detailed notes to the financial statements, covering accounting policies, customer relationships, and related party transactions - The company adopted the new revenue recognition standard (ASU 2014-09) on January 1, 2018, with no material impact. Revenue is recognized when goods are shipped and control is transferred to the customer[215](index=215&type=chunk)[216](index=216&type=chunk) - One major distributor customer accounted for approximately **58% of gross product revenues** for the twelve months ended December 31, 2018[245](index=245&type=chunk) - The company leases its main building from an entity in which a board member, Mark Pastreich, is a principal. Lease payments were **$132,504** for the twelve months ended December 31, 2018[232](index=232&type=chunk) - The company provides a safe harbor 401(k) plan for employees, with matching contributions totaling **$121,834 in 2018**[260](index=260&type=chunk) [Changes In and Disagreements with Accountants on Accounting and Financial Disclosures](index=43&type=section&id=Item%209.%20Changes%20In%20and%20Disagreements%20with%20Accountants%20on%20Accounting%20and%20Financial%20Disclosures) There were no changes in or disagreements with accountants on accounting and financial disclosure - None[262](index=262&type=chunk) [Controls and Procedures](index=43&type=section&id=Item%209A.%20Controls%20and%20Procedures) Based on an evaluation as of December 31, 2018, the company's management, including the CEO and CFO, concluded that its disclosure controls and procedures were effective. Management also reported that the company's internal control over financial reporting was effective as of the same date - Management, including the CEO and CFO, concluded that as of December 31, 2018, the company's disclosure controls and procedures are effective[263](index=263&type=chunk) - Management assessed the effectiveness of internal control over financial reporting and determined that it was effective as of December 31, 2018, based on the COSO framework[266](index=266&type=chunk) - There were no changes in internal control over financial reporting during the fourth quarter of 2018 that materially affected, or are reasonably likely to materially affect, internal controls[267](index=267&type=chunk) [Other Information](index=44&type=section&id=Item%209B.%20Other%20Information) On February 28, 2019, the company filed a corrective amendment to its Restated Certificate of Incorporation - The Company filed a corrective amendment to its Restated Certificate of Incorporation on February 28, 2019, to accurately reflect the corporate office location and include a previously omitted page[268](index=268&type=chunk) PART III This section incorporates by reference information regarding the company's directors, executive officers, compensation, security ownership, related party transactions, and principal accountant fees [Directors, Executive Officers, and Corporate Governance](index=44&type=section&id=Item%2010.%20Directors%2C%20Executive%20Officers%2C%20and%20Corporate%20Governance) Information required by this item is incorporated by reference from the company's Proxy Statement for its 2019 Annual Meeting of Shareholders. Information regarding executive officers is also presented in Part I, Item 1 of this report - Information regarding directors, corporate governance, and compliance with Section 16(a) is incorporated by reference from the 2019 Annual Meeting Proxy Statement[270](index=270&type=chunk) [Executive Compensation](index=44&type=section&id=Item%2011.%20Executive%20Compensation) Information required by this item is incorporated by reference from the company's Proxy Statement for its 2019 Annual Meeting of Shareholders - Information regarding executive compensation is incorporated by reference from the 2019 Annual Meeting Proxy Statement[271](index=271&type=chunk) [Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters](index=44&type=section&id=Item%2012.%20Security%20Ownership%20of%20Certain%20Beneficial%20Owners%20and%20Management%20and%20Related%20Stockholder%20Matters) Information required by this item is incorporated by reference from the company's Proxy Statement for its 2019 Annual Meeting of Shareholders - Information regarding security ownership is incorporated by reference from the 2019 Annual Meeting Proxy Statement[272](index=272&type=chunk) [Certain Relationships and Related Transactions and Director Independence](index=45&type=section&id=Item%2013.%20Certain%20Relationships%20and%20Related%20Transactions%20and%20Director%20Independence) Information required by this item is incorporated by reference from the company's Proxy Statement for its 2019 Annual Meeting of Shareholders - Information regarding related party transactions and director independence is incorporated by reference from the 2019 Annual Meeting Proxy Statement[273](index=273&type=chunk) [Principal Accountant Fees and Services](index=45&type=section&id=Item%2014.%20Principal%20Accountant%20Fees%20and%20Services) Information required by this item is incorporated by reference from the company's Proxy Statement for its 2019 Annual Meeting of Shareholders - Information regarding principal accountant fees and services is incorporated by reference from the 2019 Annual Meeting Proxy Statement[274](index=274&type=chunk) PART IV This section lists all exhibits and financial statement schedules filed with the report, including corporate governance documents and certifications [Exhibits and Financial Statement Schedules](index=45&type=section&id=Item%2015.%20Exhibits%20and%20Financial%20Statement%20Schedules) This section lists the exhibits filed with or incorporated by reference into the Form 10-K, including the Certificate of Incorporation, bylaws, material contracts, and certifications by the CEO and CFO - All financial statement schedules have been omitted as they are not required or applicable[276](index=276&type=chunk) - A list of exhibits filed with the report is provided, including corporate governance documents, employment agreements, and Sarbanes-Oxley certifications[278](index=278&type=chunk)[279](index=279&type=chunk) [Form 10-K Summary](index=46&type=section&id=Item%2016.%20Form%2010-K%20Summary) No summary is provided in this section - None[280](index=280&type=chunk)